Stockreport

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) [Yahoo! Finance]

Moleculin Biotech, Inc.  (MBRX) 
Last moleculin biotech, inc. earnings: 8/16 05:35 pm Check Earnings Report
US:NASDAQ Investor Relations: moleculin.com/investors
PDF – Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models HOUSTON May 15, 2024 [Read more]